Zyon Ayni, Founder and CEO of Code Pharma, updated the readers of TradeArabia about the process of their new medication: “Codivir showed great success in clinical trials and already has received emergency approvals in different countries for the treatment of coronavirus patients. Our team at Code Pharma are now initiating a multi-country phase 2 study with a larger cohort and has submitted additional emergency approval requests to several affected countries”.
Ayni added: “Our phase 2 controlled study will be conducted in Spain, Brazil, South Africa, and Israel, with a larger cohort. In view of the submitted emergency approval requests and to meet the expected demand, the company is preparing for mass production of Codivir in different sites worldwide, starting in parallel with the phase 2 trial”.
